Magnetic fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 999-1004

  Jing, Hongmei ^a   Wang, Jing ^a   Yang, Ping ^a   Ke, Xiaoyan ^a   Xia, Guohua ^b   Chen, Baoan ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Apoptosis; Magnetic nanoparticles; NF B; P53; Raji cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN P53; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRYPAN BLUE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; MAGNETITE NANOPARTICLE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RAJI CELL; RECEPTOR DOWN REGULATION; UPREGULATION; WESTERN BLOTTING; CELL SURVIVAL; CHEMISTRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DAUNORUBICIN; DOXORUBICIN; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; MAGNETITE NANOPARTICLES; NF-KAPPA B; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954555860     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14957     Document Type: Article

References (26)

1. Doroshow JH. Anthracyclines and anthracenediones. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001.
2. Herr I, Gassler N, Friess H, Buchler MW. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis. 2007; 12:271-291.
3. Nuutinen U, Ropponen A, Suoranta S, et al. Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3. Leuk Res. 2009;33:1714-1717.
4. Sui LL, Moore MJ. Pharmacology of anticancer drugs. In: Tannock IF, Hill RP, Bristow RG, Harrington L, editors. The Basic Science of Oncology. 4th ed. New York, NY: McGraw-Hill; 2005.
5. Tokimoto C. Cancer management: A multidisciplinary approach: Medical, surgical, and radiation oncology. In: Pzadur R, editor. Principles of Chemotherapy. 8th ed. New York, NY: PPR; 2004.
6. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine (Lond). 2006;1: 157-168.
7. Dave SR, Gao XH. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: A versatile and evolving technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1: 583-609.
8. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci. 1998;87:1305-1307.
9. Lin BL, Shen XD, Cui S. Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties. Biomed Mater. 2007;2:132-134.
10. Jarpe MB, Widmann C, Knall C, et al. Anti-apoptotic versus proapoptotic signal transduction: Checkpoints and stop signs along the road to death. Oncogene. 1998;17:1475-1482.
11. Karin M, Greten FR. NF-kappa B: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5: 749-759.
12. Levine AJ, Oren M. The first 30 years of p53: Growing ever more complex. Nat Rev Cancer. 2009;9:749-758.
13. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995;7:541-546.
14. Sun Q, Chen BA, Wang XM, et al. Preparation of Fe3O4-magnetic nanoparticles loaded with adriamycin and its reversal of multidrug resistance in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15: 748-751.
15. Yan F, JiangY, Li YM, Zhen X, Cen J, Fang WR. Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 isomers, tetrataisohydroquinolin derivatives. Biol Pharm Bull. 2008;31:1263-1264.
16. Zhao YP, Chen G, Feng B, et al. Microarray analysis of gene expression pro?le of multidrug resistance in pancreatic cancer. Chin Med J (Engl). 2007;120:1743-1752.
17. Devita VT. Dose response in alive and well. J Clin Oncol. 1986;4: 1157-1159.
18. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporine A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000;21:1-7.
19. Zhang RY, Wang XM, Wu CH, et al. Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology. 2006;17:3622-3626.
20. Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine. 2009;4:65-71.
21. Wang JQ, Chen BA, Cheng J, Xu WL, Sun XC. Comparison of reversal effects of 5-bromotetrandrine and tetrandrine on P-glycoprotein- dependent resistance to adriamycin in human leukemia cell line K562/A02. Ai Zheng. 2008;27:491-495.
22. Kerr JF, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
23. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy. Blood. 2005;106:3150-3159.
24. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
25. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kappa B/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia. 2004; 18:11-17.
26. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F. Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: Role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009;157:294-306.